New Delhi: Pharmaceutical giant Cipla Ltd posted a 33% decline in its consolidated net profit for the January-March quarter to ₹246 crore as the company’s operational performance was weakened by the covid-19 disruption and high base for sales last year.
Cipla’s consolidated operating margin contracted by 7 percentage points to 15%, with 2 percentage points being the impact from covid-19 related extension in cut-off, the company said in a release.
The reporting quarter also saw the normalisation of margins and US revenue as the corresponding period last year saw robust sales of its anti-hyperparathyroidism drug cinacalcet in the US.